These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28805705)

  • 21. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis.
    Thongprayoon C; Acharya P; Aeddula NR; Torres-Ortiz A; Bathini T; Sharma K; Ungprasert P; Watthanasuntorn K; Suarez MLG; Salim SA; Kaewput W; Chenbhanich J; Mao MA; Cheungpasitporn W
    Arch Osteoporos; 2019 Mar; 14(1):35. PubMed ID: 30852679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.
    Hattori K; Hirano Y; Kanayama Y; Takahashi N; Ishiguro N; Kojima T
    Nagoya J Med Sci; 2019 Nov; 81(4):571-585. PubMed ID: 31849375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization.
    Martínez-Reina J; Pivonka P
    Bone; 2019 Aug; 125():87-95. PubMed ID: 31055117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone Loss After Denosumab: Only Partial Protection with Zoledronate.
    Reid IR; Horne AM; Mihov B; Gamble GD
    Calcif Tissue Int; 2017 Oct; 101(4):371-374. PubMed ID: 28500448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
    Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
    J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
    Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
    Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
    Nakamura Y; Suzuki T; Yoshida T; Yamazaki H; Kato H
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Serum 25(OH)D
    Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
    Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy.
    Kutilek S
    Acta Med Iran; 2017 Oct; 55(10):658-660. PubMed ID: 29228533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.